Metformin as a Potential Antitumor Agent

Petrovic, Andjela; Markovic, Vladimir; Maric, Veljko; Gajovic, Nevena

doi:10.2478/sjecr-2022-0023

Abstract

Some recent findings suggest that metformin, an oral antidiabetic drug, may have antitumor properties. Studies have shown that metformin can alter cell metabolism, both tumor and immune cells, which can greatly influence disease outcome. In this review, we discuss the potential mechanisms in which metformin can directly induce apoptosis of tumor cells as well as mechanisms in which metformin can elicit or enhance antitumor immune response.

References

1. Schernthaner G, Schernthaner GH. The right place for metformin today. Diabetes Res Clin Pract. 2020;159:107946. doi: 10.1016/j.diabres.2019.107946.31778746
Open DOI Search in Google Scholar Back to article
2. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253-70.10.1042/CS20110386339886222117616
Search in Google Scholar Back to article
3. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3(Pt 3):607-14.10.1042/bj3480607
Search in Google Scholar Back to article
4. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542-6.10.1038/nature13270407424424847880
Search in Google Scholar Back to article
5. Polianskyte-Prause Z, Tolvanen TA, Lindfors S, Dumont V, Van M, Wang H, et al. Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. FASEB J. 2019;33(2):2858-2869.10.1096/fj.201800529RR633864430321069
Search in Google Scholar Back to article
6. Turban S, Stretton C, Drouin O, Green CJ, Watson ML, Gray A, et al. Defining the contribution of AMPactivated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells. J Biol Chem. 2012;287(24):20088-99.10.1074/jbc.M111.330746337019222511782
Search in Google Scholar Back to article
7. Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015;75(10):1071-94.10.1007/s40265-015-0416-8449827926059289
Search in Google Scholar Back to article
8. Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. CurrObes Rep. 2019;8(2):156-164.10.1007/s13679-019-00335-3652018530874963
Search in Google Scholar Back to article
9. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27-31.
Search in Google Scholar Back to article
10. Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother. 2013;47(10):1348-52.10.1177/106002801350310824259699
Search in Google Scholar Back to article
11. Kuan W, Beavers CJ, Guglin ME. Still sour about lactic acidosis years later: role of metformin in heart failure. Heart Fail Rev. 2018;23(3):347-353.10.1007/s10741-017-9649-928868582
Search in Google Scholar Back to article
12. Mohan M, Al-Talabany S, McKinnie A, Mordi IR, Singh JSS, Gandy SJ, et al. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the METREMODEL trial. Eur Heart J. 2019;40(41):3409-3417.10.1093/eurheartj/ehz203682361530993313
Search in Google Scholar Back to article
13. Bell S, Farran B, McGurnaghan S, McCrimmon RJ, Leese GP, Petrie JR, et al. Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrol. 2017;18(1):163.10.1186/s12882-017-0579-5543741128526011
Search in Google Scholar Back to article
14. Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019;21(5):1199-1208.10.1111/dom.1364230672083
Search in Google Scholar Back to article
15. Valencia WM, Palacio A, Tamariz L, Florez H. Metformin and ageing: improving ageing outcomes beyond glycaemic control. Diabetologia. 2017;60(9):1630-1638.10.1007/s00125-017-4349-5570920928770328
Search in Google Scholar Back to article
16. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2(6):57.
Search in Google Scholar Back to article
17. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014;132(2):438-42.10.1016/j.ygyno.2013.11.02124269517
Search in Google Scholar Back to article
18. Feng JL, Qin X. Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study. Diabetes Res Clin Pract. 2021;175:108755. doi: 10.1016/j.diabres.2021.108755.33836207
Open DOI Search in Google Scholar Back to article
19. Li K, Zhang TT, Wang F, Cui B, Zhao CX, Yu JJ, et al. Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression. Oncogene. 2018;37(22):2967-2981.10.1038/s41388-018-0172-929520103
Search in Google Scholar Back to article
20. Lan B, Zhang J, Zhang P, Zhang W, Yang S, Lu D, et al. Metformin suppresses CRC growth by inducing apoptosis via ADORA1. Front Biosci (Landmark Ed). 2017;22:248-257.10.2741/448427814614
Search in Google Scholar Back to article
21. Kahn BB, Alquier T, Carling D, Hardie DG. AMPactivated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15-25.10.1016/j.cmet.2004.12.00316054041
Search in Google Scholar Back to article
22. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf). 2009;196(1):65-80.10.1111/j.1748-1716.2009.01972.x276030819245654
Search in Google Scholar Back to article
23. Tian, Tian & Li, Xiaoyi & Zhang, Jinhua. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. International Journal of Molecular Sciences. 2019;20(3):755.10.3390/ijms20030755638704230754640
Search in Google Scholar Back to article
24. Lu CC, Chiang JH, Tsai FJ, Hsu YM, Juan YN, Yang JS, et al. Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. Int J Oncol. 2019;54(4):1271-1281.
Search in Google Scholar Back to article
25. Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One. 2014;9(5):e98207. doi: 10.1371/journal.pone.0098207.403229324858012
Open DOI Search in Google Scholar Back to article
26. Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, et al. Metformin Enhances Cisplatin Induced Apoptosis and Prevents Resistance to Cisplatin in Comutated KRAS/LKB1 NSCLC. J. Thorac. Oncol. 2018;13(11):1692–1704.
Search in Google Scholar Back to article
27. Zhao Y, Zhang E, Lv N, Ma L, Yao S, Yan M, et al. Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells. Cell. Physiol. Biochem. 2018;48:785–800.
Search in Google Scholar Back to article
28. Wang L, Li K, Lin X, Yao Z, Wang S, Xiong X, et al. Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis. Cancer Lett. 2019;450:22-31.10.1016/j.canlet.2019.02.01430771436
Search in Google Scholar Back to article
29. Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017;277(1):61-75.10.1111/imr.12534541682228462526
Search in Google Scholar Back to article
30. Zheng Z, Bian Y, Zhang Y, Ren G, Li G. Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDMEmediated cancer cell pyroptosis. Cell Cycle. 2020;19(10):1089-1104.10.1080/15384101.2020.1743911721736832286137
Search in Google Scholar Back to article
31. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008;9:662–73.10.2174/138945008785132402267457518691013
Search in Google Scholar Back to article
32. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381(6585):800-3.10.1038/381800a08657285
Search in Google Scholar Back to article
33. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. BiochimBiophys Acta. 2002;1585(2-3):193-201.10.1016/S1388-1981(02)00341-412531554
Search in Google Scholar Back to article
34. Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, et al. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019;17(4):870-881.10.1158/1541-7786.MCR-18-0409644568930655321
Search in Google Scholar Back to article
35. Wang X, Sun Y, Peng X, Naqvi SMAS, Yang Y, Zhang J, et al. The Tumorigenic Effect of Sphingosine Kinase 1 and Its Potential Therapeutic Target. Cancer Control. 2020;27(1):1073274820976664. doi: 10.1177/1073274820976664.848035533317322
Open DOI Search in Google Scholar Back to article
36. Matsuzawa A, Nishitoh H, Tobiume K, Takeda K, Ichijo H. Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: advanced findings from ASK1 knockout mice. Antioxid Redox Signal. 2002;4(3):415-25.10.1089/1523086026019621812215209
Search in Google Scholar Back to article
37. Ma L, Wei J, Wan J, Wang W, Wang L, Yuan Y, et al. Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Exp Clin Cancer Res. 2019;38(1):77.10.1186/s13046-019-1090-6637518730760281
Search in Google Scholar Back to article
38. Yi Y, Zhang W, Yi J, Xiao ZX. Role of p53 Family Proteins in Metformin Anti-Cancer Activities. J Cancer. 2019;10(11):2434-2442.10.7150/jca.30659658434031258748
Search in Google Scholar Back to article
39. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-331.10.1016/S0092-8674(00)81871-19039259
Search in Google Scholar Back to article
40. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci. 2003;116:4077–85.10.1242/jcs.0073912972501
Search in Google Scholar Back to article
41. Yudhani RD, Astuti I, Mustofa M, Indarto D, Muthmainah M. Metformin Modulates Cyclin D1 and P53 Expression to Inhibit Cell Proliferation and to Induce Apoptosis in Cervical Cancer Cell Lines. Asian Pac J Cancer Prev. 2019;20(6):1667-1673.10.31557/APJCP.2019.20.6.1667702160631244286
Search in Google Scholar Back to article
42. Chen YH, Yang SF, Yang CK, Tsai HD, Chen TH, Chou MC, et al. Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells. Mol Med Rep. 2021;23(1):88.10.3892/mmr.2020.11725771642633236135
Search in Google Scholar Back to article
43. Li P, Zhao M, Parris AB, Feng X, Yang X. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. BiochemBiophys Res Commun. 2015;464(4):1267-1274.10.1016/j.bbrc.2015.07.11726225749
Search in Google Scholar Back to article
44. Ahn HK, Lee YH, Koo KC. Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review. Int J Mol Sci. 2020;21(22):8540.10.3390/ijms21228540769814733198356
Search in Google Scholar Back to article
45. Sun Y, Tao C, Huang X, He H, Shi H, Zhang Q, et al. Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway. Onco Targets Ther. 2016;9:2845-53.
Search in Google Scholar Back to article
46. Tran LNK, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, et al. The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer. Mol Cancer Ther. 2017;16(12):2689-2700.10.1158/1535-7163.MCT-17-007428802253
Search in Google Scholar Back to article
47. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70(6):2465-75.10.1158/0008-5472.CAN-09-278220215500
Search in Google Scholar Back to article
48. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014;5(2):e1088. doi: 10.1038/cddis.2014.59.394427124577086
Open DOI Search in Google Scholar Back to article
49. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.10.1038/nrc2734485602519851315
Search in Google Scholar Back to article
50. Nielsen M, Kaestel CG, Eriksen KW, Woetmann A, Stokkedal T, Kaltoft K, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999;13(5):735-8.10.1038/sj.leu.240141510374878
Search in Google Scholar Back to article
51. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11(2):367-76.10.4161/cc.11.2.1881322189713
Search in Google Scholar Back to article
52. Griffiths CL, Olin JL. Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract. 2012;25(3):319-23.10.1177/089719001244206222551559
Search in Google Scholar Back to article
53. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011;2(9):e199. doi: 10.1038/cddis.2011.86.318690421881601
Open DOI Search in Google Scholar Back to article
54. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27(48):6194-206.10.1038/onc.2008.29718931687
Search in Google Scholar Back to article
55. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol. 2008;14(47):7192-8.10.3748/wjg.14.7192498835619084933
Search in Google Scholar Back to article
56. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007;64(10):1290-302.10.1007/s00018-007-7080-417447005
Search in Google Scholar Back to article
57. Gao ZY, Liu Z, Bi MH, Zhang JJ, Han ZQ, Han X, et al. Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Exp Ther Med. 2016;11(5):1700-1706.10.3892/etm.2016.3143484052627168791
Search in Google Scholar Back to article
58. Takahashi A, Kimura F, Yamanaka A, Takebayashi A, Kita N, Takahashi K, et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 2014;14:53. doi: 10.1186/1475-2867-14-53.407040124966801
Open DOI Search in Google Scholar Back to article
59. Jang JH, Sung EG, Song IH, Lee TJ, Kim JY. Metformin induces caspase-dependent and caspase-independent apoptosis in human bladder cancer T24 cells. Anticancer Drugs. 2020;31(7):655-662.10.1097/CAD.0000000000000966736567032568826
Search in Google Scholar Back to article
60. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PDL1. Mol Cell. 2018;71(4):606-620.10.1016/j.molcel.2018.07.030678649530118680
Search in Google Scholar Back to article
61. Yu W, Hua Y, Qiu H. et al. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis 11, 506 (2020).10.1038/s41419-020-2701-z733845732632098
Search in Google Scholar Back to article
62. Jovanovic M, Gajovic N, Lukic M, Popovic A, Jovanovic IP. Synergism of PDL/PD1 and IL33/ST2 axis in tumor immunology. Ser J Exp Clin Res. 2019;20(3):223-228.10.2478/sjecr-2018-0033
Search in Google Scholar Back to article
63. Jovanovic M, Gajovic N, Jurisevic M, Sekulic S, Arsenijevic N, Jocic M, et al. Anti PD1 therapy activates tumoricidic properties of NKT cells and contributes to overall deceleration of tumor progression in a model of murine mammary carcinoma. Vojnosanitpregl. 2021; doi: 10.2298/VSP210126039J
Open DOI Search in Google Scholar Back to article
64. Jovanovic M, Geller D, Gajovic N, Jurisevic M, Arsenijevic N, Jovanovic M, et al. Dual blockage of PD-L/PD-1 and IL33/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells. Life Sciences. 2022;289:120214. doi.org/10.1016/j.lfs.2021.12021410.1016/j.lfs.2021.12021434890591
Search in Google Scholar Back to article
65. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-742.
Search in Google Scholar Back to article
66. Zhang JJ, Zhang QS, Li ZQ, Zhou JW, Du J. Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells. Am J Transl Res. 2019;11(11):6965-6976.
Search in Google Scholar Back to article
67. Xue J, Li L, Li N, Li F, Qin X, Li T, et al. Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1. Eur J Pharmacol. 2019;15;859:172541. doi: 10.1016/j.ejphar.2019.172541.31319067
Open DOI Search in Google Scholar Back to article
68. Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017;9(3):289-302.10.2217/imt-2016-0135561905228231720
Search in Google Scholar Back to article
69. Ding L, Liang G, Yao Z, Zhang J, Liu R, Chen H, et al. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget. 2015;6(34):36441-55.10.18632/oncotarget.5541474218826497364
Search in Google Scholar Back to article
70. Saito A, Kitayama J, Horie H, Koinuma K, Ohzawa H, Yamaguchi H, et al. Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. Cancer Sci. 2020;111(11):4012-4020.10.1111/cas.14615764804232794612
Search in Google Scholar Back to article
71. Chiang CF, Chao TT, Su YF, Hsu CC, Chien CY, Chiu KC, et al. Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling. Oncotarget. 2017;8(13):20706-20718.10.18632/oncotarget.14982540053828157701
Search in Google Scholar Back to article
72. Ma Q, Gu JT, Wang B, Feng J, Yang L, Kang XW, et al. PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin. Eur J Pharmacol. 2019; 15;863:172696. doi: 10.1016/j.ejphar.2019.172696.31562866
Open DOI Search in Google Scholar Back to article
73. St Paul M, Ohashi PS. The Roles of CD8+ T Cell Subsets in Antitumor Immunity. Trends Cell Biol. 2020;30(9):695-704.10.1016/j.tcb.2020.06.00332624246
Search in Google Scholar Back to article
74. Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19(11):665-674.10.1038/s41577-019-0221-9728644131570879
Search in Google Scholar Back to article
75. Watanabe M, Eikawa S, Shien K, Yamamoto H, Shien T, Soh J, et al. Abstract 5592: metformin improves immune function of exhausted peripheral CD8+ T cells derived from cancer patients. Cancer Res. 2017; 77(13 Suppl):5592–5592.10.1158/1538-7445.AM2017-5592
Search in Google Scholar Back to article
76. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112(6):1809-14.10.1073/pnas.1417636112433073325624476
Search in Google Scholar Back to article
77. Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C, et al. Metformin Enhances the Antitumor Activity of CD8+ T Lymphocytes via the AMPK-miR-107-Eomes-PD-1 Pathway. J Immunol. 2020;204(9):2575-2588.10.4049/jimmunol.190121332221038
Search in Google Scholar Back to article
78. Kunisada Y, Eikawa S, Tomonobu N, Domae S, Uehara T, Hori S, et al. Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug. EBioMedicine. 2017;25:154-164.10.1016/j.ebiom.2017.10.009570405329066174
Search in Google Scholar Back to article
79. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080-2089.10.1111/cas.14069660981331102428
Search in Google Scholar Back to article
80. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-61.10.1126/science.107949012522256
Search in Google Scholar Back to article
81. Wei L, Luo Z, Li J, Li H, Liang Y, Li J, et al. Metformin inhibits proliferation and functions of regulatory T cells in acidic environment. 2019;39(12):1427-1435.
Search in Google Scholar Back to article
82. Pereira FV, Melo ACL, Low JS, de Castro ÍA, Braga TT, Almeida DC, et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget. 2018;9(40):25808-25825.10.18632/oncotarget.25380599525329899823
Search in Google Scholar Back to article
83. Reiser J, Banerjee A. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res. 2016;2016:8941260. doi: 10.1155/2016/8941260.489344027314056
Open DOI Search in Google Scholar Back to article
84. Zhao D, Long XD, Lu TF, Wang T, Zhang WW, Liu YX, et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer. 2015;136(11):25 56-65.10.1002/ijc.2930525370454
Search in Google Scholar Back to article
85. Peng Y, Gao X, Yang J. et al. Interleukin-22 Promotes T Helper 1 (Th1)/Th17 Immunity in Chlamydial Lung Infection. Mol Med 20, 2014; 109–119.10.2119/molmed.2013.00115396039724531835
Search in Google Scholar Back to article
86. Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, et al. Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer. Cancer Res. 2018;78(7):1779-1791.10.1158/0008-5472.CAN-17-2460588258929374065
Search in Google Scholar Back to article
87. Xu P, Yin K, Tang X, Tian J, Zhang Y, Ma J, et al. Metformin inhibits the function of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Biomed Pharmacother. 2019;120:109458. doi: 10.1016/j.biopha.2019.109458.31550676
Open DOI Search in Google Scholar Back to article
88. Hirayama T, Nagata Y, Nishida M, Matsuo M, Kobayashi S, Yoneda A, et al. Metformin Prevents Peritoneal Dissemination via Immune-suppressive Cells in the Tumor Microenvironment. Anticancer Res. 2019;39(9):4699-4709.10.21873/anticanres.1365231519569
Search in Google Scholar Back to article
89. Qin G, Lian J, Huang L, Zhao Q, Liu S, Zhang Z, et al. Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. Oncoimmunology. 2018;7(7):e1442167. doi: 10.1080/21624 02X.2018.1442167.
Open DOI Search in Google Scholar Back to article
90. Uehara T, Eikawa S, Nishida M, Kunisada Y, Yoshida A, Fujiwara T, et al. Metformin induces CD11b+-cellmediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects. Int Immunol. 2019;31(4):187-198.10.1093/intimm/dxy079644044130508092
Search in Google Scholar Back to article
91. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61(2):255-263.10.1007/s00262-011-1161-922120756
Search in Google Scholar Back to article
92. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010;59(10):1593-600.10.1007/s00262-010-0855-8370626120414655
Search in Google Scholar Back to article
93. Gajovic N, Jurisevic M, Pantic J, Radosavljevic G, Arsenijevic N, Lukic ML, et al. Attenuation of NK cells facilitates mammary tumor growth in streptozotocin-induced diabetes in mice. Endocrine-related cancer 2018; 25: 493-507.10.1530/ERC-17-052929459428
Search in Google Scholar Back to article
94. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856-93.10.3390/cancers3043856376340024213115
Search in Google Scholar Back to article
95. Karadeniz Z, Aynacıoğlu AŞ, Bilir A, Tuna MY. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy. Med Hypotheses. 2020;134:e109420. doi: 10.1016/j.mehy.2019.109420.31634770
Open DOI Search in Google Scholar Back to article
96. Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39(10):2040-2054.10.1038/s41388-019-1124-831801970
Search in Google Scholar Back to article
97. Mishra A. K., Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia, 2019;33(11), 2695-2709.10.1038/s41375-019-0470-430988378
Search in Google Scholar Back to article
98. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553-11572.10.1007/s13277-016-5098-727260630
Search in Google Scholar Back to article
99. Kang S, Kim BR, Kang MH, Kim DY, Lee DH, Oh SC, et al. Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells. PLoS One. 2018;13(10):e0205449. doi: 10.1371/journal.pone.0205449.618137530308035
Open DOI Search in Google Scholar Back to article
100.Shuchen Gu, Xin-Hua Feng. TGF-β signaling in cancer, Acta Biochimica et BiophysicaSinica, 2018;50(10):941-949.
Search in Google Scholar Back to article
101.Gajovic N, Jovanovic I, Ilic A, Jeremic N, Jakovljevic V, Arsenijevic N, et al. Diabetes mellitus directs NKT cells toward type 2 and regulatory phenotype Ser J Exp Clin Res. 2016; 17 (1): 35-41.
Search in Google Scholar Back to article
102.Xiao H, Zhang J, Xu Z, et al. Metformin is a novel suppressor for transforming growth factor (TGF)-β1. Sci Rep. 2016;6:28597. doi: 10.1038/srep28597492385827349853
Open DOI Search in Google Scholar Back to article
103.Leonel C, Borin TF, de Carvalho Ferreira L, Moschetta MG, Bajgelman MC, Viloria-Petit AM, et al. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model. J Mammary Gland Biol Neoplasia. 2017;22(1):27-41.10.1007/s10911-016-9370-728078601
Search in Google Scholar Back to article
104.Song Y, Chen Y, Li Y, Lyu X, Cui J, Cheng Y, et al. Metformin inhibits TGF-β1-induced epithelial-to-mesenchymal transition-like process and stem-like properties in GBM via AKT/mTOR/ZEB1 pathway. Oncotarget. 2017;9(6):7023-7035.10.18632/oncotarget.23317580553329467947
Search in Google Scholar Back to article
105.Chengye W, Yu T, Ping S, Deguang S, Keyun W, Yan W, et al. Metformin reverses bFGF-induced epithelialmesenchymal transition in HCC cells. Oncotarget. 2017;8(61):104247-104257.10.18632/oncotarget.22200573280329262637
Search in Google Scholar Back to article

Metformin as a Potential Antitumor Agent

Abstract

Paradigm

My account